Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market latest Statistics on Market Size, Growth, Production, Sales Volume, Sales Price, Market Share and Import vs Export 

Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market Summary Highlights

The Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market is being shaped by sustained expansion in long-acting drug delivery systems, absorbable implant technologies, and controlled-release injectable formulations. In 2026, the global market size is estimated at approximately USD 980 million, supported by rising utilization of biodegradable polymers across oncology therapeutics, orthopedic fixation devices, tissue engineering scaffolds, and microsphere-based formulations. Pharmaceutical outsourcing activity and increasing FDA approvals for sustained-release products continue to strengthen commercial demand for medical-grade PLGA materials with tightly controlled degradation profiles and molecular weight specifications.

Demand concentration remains strongest in North America and Western Europe due to advanced injectable drug pipelines and higher adoption of bioresorbable medical materials, while East Asia is emerging as a manufacturing and formulation hub. China, South Korea, and India are increasing investments in polymer processing capacity for regulated healthcare applications. The market is also seeing a measurable shift toward customized copolymer ratios and low-residual monomer grades to improve drug encapsulation efficiency and predictable release kinetics.

Recent developments across the ecosystem are reinforcing investment activity. In March 2026,  expanded its RESOMER bioresorbable polymer manufacturing support network for injectable therapeutics and implantable devices, targeting higher pharmaceutical outsourcing demand from North America and Europe. In January 2026,  announced additional medical biomaterials collaborations focused on resorbable polymer applications for orthopedic and regenerative medicine platforms. In October 2025, the  cleared multiple extended-release injectable submissions utilizing PLGA-based microsphere delivery systems, reinforcing commercial scalability for biodegradable excipient technologies.

Statistical Snapshot – Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market

• Global Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market estimated at nearly USD 980 million in 2026.
• Forecast market valuation projected to exceed USD 1.85 billion by 2032.
• Long-acting injectable formulations account for approximately 38% of total PLGA consumption volume in 2026.
• Drug delivery applications contribute nearly 52% of total revenue generation globally.
• 75:25 and 50:50 lactide-to-glycolide copolymer ratios collectively represent over 46% of commercial demand.
• North America maintains around 36% share of global revenue due to strong biologics and injectable therapeutics production.
• Asia-Pacific medical polymer demand expected to expand at more than 11.5% CAGR through 2032.
• Orthopedic and trauma fixation applications projected to cross USD 240 million in annual PLGA material demand by 2028.
• Pharmaceutical contract manufacturing utilization of medical-grade PLGA materials increased by nearly 14% between 2024 and 2026.
• Microsphere-based sustained-release therapeutics pipeline expanded by over 18% globally during 2025–2026.
• Bioabsorbable implant procedures using PLGA-derived materials surpassed 9.2 million annual units globally in 2026.
• Controlled-release oncology formulations contribute approximately 21% of pharmaceutical-grade PLGA consumption.

Long-Acting Injectable Therapies Continue Expanding Polymer Demand

One of the strongest demand drivers for the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market is the rapid expansion of long-acting injectable therapeutics. Pharmaceutical manufacturers are increasingly relying on biodegradable polymers to improve dosing intervals, reduce hospitalization frequency, and enhance patient compliance in chronic disease management.

PLGA-based microspheres are widely used in depot formulations for oncology, diabetes, schizophrenia, hormone therapy, and pain management. Injectable sustained-release products using biodegradable polymer encapsulation are gaining preference because they reduce administration frequency from daily dosing to monthly or even quarterly intervals. This trend is particularly visible in central nervous system therapeutics and peptide-based drugs.

In February 2026,  expanded development activity around ultra-long-acting oral and injectable delivery technologies involving bioresorbable polymer systems. Similar investment momentum is visible across specialty pharma manufacturers focusing on depot injections.

The commercial significance is substantial. Global sales of long-acting injectable pharmaceuticals are estimated to exceed USD 78 billion in 2026, with biodegradable polymer carriers representing a critical enabling technology segment. More than 320 injectable drug candidates globally are currently being evaluated with sustained-release delivery mechanisms, creating direct raw material demand for pharmaceutical-grade PLGA polymers with highly specific viscosity and degradation characteristics.

Regulatory approvals are also supporting higher material standardization. Pharmaceutical companies increasingly require polymers manufactured under GMP-compliant conditions with traceable residual solvent levels, endotoxin control, and reproducible molecular weight distribution. This has strengthened pricing stability for high-purity medical-grade materials compared to industrial biodegradable polymers.

Orthopedic Bioabsorbable Implants Supporting High-Value Material Consumption

The orthopedic sector remains a major contributor to the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market due to rising adoption of absorbable fixation systems. Conventional metallic implants frequently require secondary removal surgeries, particularly in pediatric trauma and sports medicine applications. PLGA-based fixation screws, pins, anchors, and scaffolds eliminate many of these procedural complications.

Global sports injury procedures crossed 42 million annually in 2026, with minimally invasive repair procedures increasing steadily in North America, Japan, Germany, and South Korea. Orthopedic manufacturers are using biodegradable copolymers to reduce long-term foreign body complications while improving tissue compatibility.

In August 2025,  expanded commercialization of bioabsorbable fixation systems for soft tissue repair applications in ambulatory surgical settings. The trend reflects broader movement toward temporary implant technologies across orthopedic reconstruction markets.

Demand is especially strong for copolymer formulations offering controlled degradation windows between six months and two years. Higher glycolide ratios accelerate hydrolysis rates, allowing manufacturers to tailor implant performance for different tissue-healing cycles. This customization capability is increasing procurement volumes for specialty PLGA grades rather than standard commodity biomaterials.

Hospitals are also prioritizing lower post-operative complication rates. Studies published through orthopedic associations in 2025 indicated that bioabsorbable fixation systems reduced implant-removal procedures by more than 60% in selected trauma categories, supporting long-term adoption.

Tissue Engineering and Regenerative Medicine Applications Increasing

Regenerative medicine programs are creating another important demand channel for medical-grade poly(lactic-co-glycolic acid). Tissue scaffolds based on PLGA are increasingly used for cell proliferation support, guided tissue regeneration, vascular engineering, and wound healing applications.

The global regenerative medicine sector surpassed USD 48 billion in estimated commercial activity in 2026, supported by rising clinical trial activity in stem cell therapy and tissue repair technologies. PLGA scaffolds are valued for tunable porosity, biodegradation control, and compatibility with biologically active compounds.

Research institutions and biotech firms are incorporating composite scaffold systems combining PLGA with collagen, hydroxyapatite, or bioactive ceramics. These combinations are showing increasing success in bone regeneration and dental tissue engineering.

In November 2025,  highlighted expanded partnerships involving bioresorbable scaffold manufacturing for personalized regenerative medicine platforms. The use of additive manufacturing with biodegradable polymers is improving scaffold geometry precision and accelerating prototyping timelines.

This area remains relatively high value because scaffold-grade polymers require extremely controlled purity profiles and validated biocompatibility testing. Consequently, regenerative medicine applications often command premium pricing compared to standard pharmaceutical excipient usage.

Contract Manufacturing and Outsourcing Trends Strengthening Supply Networks

Another important factor influencing the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market is the growth of pharmaceutical outsourcing. Biopharmaceutical companies increasingly rely on specialized contract development and manufacturing organizations (CDMOs) for sustained-release formulation development.

This outsourcing model is increasing demand for standardized, scalable polymer supply chains. Material producers are investing in dedicated medical-grade manufacturing facilities capable of supporting regulatory submissions across multiple jurisdictions.

In April 2026, expanded pharmaceutical excipient capabilities targeting controlled-release and bioresorbable applications. Similar investments are occurring across Europe and Asia to secure regional supply resilience.

The trend gained momentum after supply chain disruptions experienced during 2021–2023 exposed vulnerabilities in specialty medical polymer sourcing. Pharmaceutical manufacturers now prefer dual-region sourcing strategies for critical excipients, benefiting suppliers with manufacturing presence in both Western markets and Asia-Pacific.

India and South Korea are attracting increased attention as secondary production hubs due to lower processing costs and improving GMP infrastructure. South Korean biomaterials exports for medical applications increased by nearly 12% during 2025–2026, supported by government-backed biotechnology incentives.

Rising Preference for Personalized Drug Delivery Architectures

Drug developers are moving away from one-size-fits-all release systems toward customized pharmacokinetic profiles. This trend is expanding the diversity of PLGA formulations used commercially.

Instead of standardized polymer grades, pharmaceutical companies increasingly request precise lactide:glycolide ratios, intrinsic viscosity ranges, particle size distribution controls, and terminal group modifications. Such customization improves encapsulation efficiency for sensitive biologics and peptides.

This evolution is particularly relevant in oncology therapeutics, where sustained local drug release can reduce systemic toxicity. Implantable chemotherapy depots and localized immunotherapy delivery systems are receiving greater clinical attention.

In September 2025, increased investment in advanced drug delivery manufacturing platforms that support complex injectable therapeutics. Material suppliers aligned with these formulation trends are gaining higher-margin opportunities within the biodegradable polymer ecosystem.

The growing complexity of biologic therapies is expected to sustain above-average demand growth for highly engineered medical-grade PLGA materials through the remainder of the decade.

Regional Demand Dynamics in the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market

The Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market continues to display highly concentrated regional demand patterns, with North America, Western Europe, and East Asia accounting for the majority of pharmaceutical and implant-grade polymer consumption. Differences in injectable drug pipelines, biologics manufacturing infrastructure, medical device regulation, and healthcare spending are creating distinct regional procurement behaviors.

North America remains the largest consumer region, contributing approximately 36% of global revenue in 2026. The United States dominates demand due to extensive use of biodegradable polymers in long-acting injectables, orthopedic fixation systems, and advanced wound care products. The   continues to support translational research involving polymer-based drug delivery systems, particularly in oncology and regenerative medicine. More than 140 active clinical programs in the U.S. currently involve biodegradable controlled-release technologies utilizing PLGA-based systems.

The pharmaceutical manufacturing ecosystem in the U.S. also supports high-value polymer consumption. Injectable drug production capacity expanded notably during 2025–2026, especially for peptide therapeutics and sustained-release formulations. This has increased procurement demand for highly purified ester-terminated and acid-terminated PLGA grades.

Western Europe represents nearly 28% of total Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market demand. Germany, Switzerland, France, and Ireland continue to attract pharmaceutical investment linked to biologics and specialty injectables. European demand is additionally supported by stricter post-surgical recovery protocols favoring absorbable implants over permanent metallic fixation devices.

Germany remains one of the strongest regional hubs for bioresorbable orthopedic products. In January 2026, expanded biomaterials integration initiatives focused on surgical and tissue repair technologies using absorbable polymer systems. European medical device manufacturers are increasingly incorporating biodegradable copolymers into sports medicine and trauma repair applications, particularly for outpatient procedures.

Asia-Pacific Becoming a Strategic Manufacturing and Consumption Center

Asia-Pacific is registering the fastest expansion within the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market, with regional demand projected to grow above 11% annually through 2032. China, Japan, South Korea, and India are strengthening both polymer production and downstream pharmaceutical formulation capabilities.

China has emerged as a major processing center for biodegradable medical polymers due to rapid expansion in injectable therapeutics manufacturing. The country’s pharmaceutical sector crossed USD 620 billion in industrial value during 2026, creating substantial internal demand for controlled-release excipients and bioabsorbable materials. Chinese orthopedic procedure volumes are also increasing sharply because of population aging and sports injury incidence.

Japan maintains strong demand for high-purity medical polymers due to advanced regenerative medicine programs. The Japanese regenerative medicine industry continues to receive policy support under accelerated approval pathways for cell-based therapies and scaffold-assisted tissue engineering technologies.

South Korea is rapidly strengthening its biomaterials export profile. In June 2025,  announced further investment into advanced biopharmaceutical manufacturing infrastructure supporting complex injectable therapies. The country’s emphasis on biologics manufacturing indirectly benefits biodegradable polymer suppliers integrated into injectable formulation supply chains.

India’s contribution is increasingly linked to contract pharmaceutical manufacturing. Injectable drug exports from India expanded substantially during 2025–2026, particularly in peptide therapeutics and oncology formulations. Domestic manufacturers are also investing in medical polymer processing capabilities to reduce reliance on imported excipients.

Market Segmentation Highlights

By Application

• Drug delivery systems account for nearly 52% of total Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market revenue in 2026.
• Orthopedic and trauma fixation applications contribute around 19%.
• Tissue engineering and regenerative medicine represent approximately 14%.
• Sutures, wound care, and bioabsorbable surgical materials collectively contribute nearly 10%.
• Ophthalmic implants and localized therapeutic systems represent emerging high-margin applications.

By Product Type

• 50:50 PLGA copolymer grades maintain the largest commercial share due to balanced degradation rates.
• 75:25 formulations are seeing increased demand in long-duration drug release systems.
• Acid-terminated polymers are preferred in microsphere drug encapsulation applications.
• Ester-terminated grades continue gaining usage in implantable medical devices due to slower hydrolysis behavior.

By End User

• Pharmaceutical manufacturers account for over 48% of total demand.
• Medical device companies contribute approximately 31%.
• Contract development and manufacturing organizations continue increasing share due to outsourcing trends.
• Academic and regenerative medicine research institutes remain important consumers of customized laboratory-scale polymer grades.

By Region

• North America: ~36% market share
• Europe: ~28%
• Asia-Pacific: ~29%
• Latin America and Middle East & Africa combined: ~7%

Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Production Trends

Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) production is becoming increasingly specialized as pharmaceutical and implant manufacturers require tighter control over molecular weight distribution, residual solvents, and degradation profiles. Global Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) production exceeded 7,800 metric tons in 2026, with pharmaceutical applications accounting for the majority of output volume. North America and Europe continue to dominate high-purity Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) production, although Asia-Pacific capacity additions are accelerating. China increased biodegradable medical polymer manufacturing capacity by nearly 13% between 2024 and 2026, while South Korean producers expanded GMP-certified polymer processing lines focused on injectable therapeutics. Manufacturers are increasingly shifting toward batch traceability systems and low-endotoxin processing technologies to comply with tightening pharmaceutical standards. Capacity utilization rates for premium medical-grade PLGA facilities remained above 78% globally during 2026, reflecting relatively tight supply conditions for regulated healthcare applications.

Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Price Structure Influenced by Purity and Regulatory Standards

The Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Price environment remains fundamentally different from industrial biodegradable polymer markets because pricing is heavily influenced by regulatory qualification requirements and pharmaceutical-grade processing standards.

Average Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Price levels in 2026 range between USD 820 and USD 2,600 per kilogram depending on copolymer ratio, molecular weight specification, and endotoxin compliance requirements. Research-grade materials occupy the lower pricing band, while injectable pharmaceutical grades and customized release-profile polymers command premium pricing.

High-purity polymers used in depot formulations continue experiencing tighter supply-demand conditions because pharmaceutical manufacturers require validated GMP documentation, low residual catalysts, and narrow viscosity tolerances. These quality requirements significantly increase production costs relative to commodity bioplastics.

Raw material volatility also influences Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Price Trend patterns. Lactide and glycolide monomer costs rose moderately during late 2025 due to higher fermentation feedstock costs and specialty purification expenses. However, long-term supply agreements between pharmaceutical companies and polymer suppliers helped stabilize pricing across regulated healthcare contracts.

Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Price Trend Reflecting Supply Chain Tightness

The Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Price Trend through 2025–2026 has shown moderate upward movement, particularly for pharmaceutical-grade customized formulations. Average global prices for injectable-grade PLGA increased by approximately 6%–8% during the period due to higher GMP manufacturing costs and rising demand from sustained-release therapeutics developers.

Regional differences remain significant. North American and European buyers continue paying premium prices because of stringent compliance requirements and preference for validated domestic or dual-source suppliers. Asian producers offer lower-cost alternatives, although qualification timelines for pharmaceutical adoption remain relatively long.

In March 2026,  indicated continued investment into bioresorbable polymer manufacturing infrastructure targeting pharmaceutical and medical device applications. Such investments are expected to gradually ease premium supply tightness, although the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Price Trend is still expected to remain elevated for highly specialized injectable grades through the next several years.

Another emerging influence on Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Price is sustainability-linked sourcing. Pharmaceutical manufacturers are increasingly evaluating lower-carbon feedstock pathways and solvent recovery systems in polymer procurement decisions. Suppliers incorporating renewable feedstock integration and closed-loop processing technologies are beginning to secure pricing advantages in European healthcare procurement contracts.

The pricing outlook therefore remains closely tied not only to raw material economics, but also to regulatory qualification complexity, injectable drug pipeline expansion, and the availability of validated high-purity manufacturing capacity.

Leading Manufacturers in the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market

The competitive environment in the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market remains concentrated among a relatively small group of manufacturers with strong expertise in biodegradable polymers, pharmaceutical excipients, and regulated biomaterials production. High entry barriers continue to limit the participation of new suppliers because medical-grade PLGA manufacturing requires GMP-certified facilities, validated purification systems, molecular weight consistency, and long-term regulatory support capabilities.

The market is largely dominated by companies supplying high-purity PLGA for long-acting injectable formulations, orthopedic implants, tissue scaffolds, and controlled drug delivery systems. Supplier relationships in this industry are typically long-term because pharmaceutical companies avoid switching polymer vendors once commercial drug approvals are secured.

Evonik Industries continues to hold the leading share in the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market. The company’s RESOMER product family remains one of the most widely used biodegradable polymer platforms for injectable therapeutics and implantable medical applications. Its product range includes customized copolymer ratios, ester-terminated and acid-terminated grades, and advanced release-control polymers designed for microspheres and depot formulations.

The company benefits significantly from strong penetration in long-acting injectable pharmaceuticals. Many sustained-release products approved across North America and Europe are already validated using RESOMER polymers, creating high supplier retention rates. Evonik also maintains strong positioning in orthopedic biomaterials and regenerative medicine scaffolds. In 2026, the company is estimated to account for approximately 28%–31% of global regulated medical-grade PLGA revenues.

Corbion Biomaterials represents another major participant in the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market through its PURASORB polymer portfolio. The company has expanded aggressively in bioabsorbable medical devices, regenerative medicine, and controlled-release drug delivery systems. Its biodegradable polymers are widely utilized in orthopedic fixation systems, tissue engineering structures, and injectable delivery applications.

Corbion’s vertically integrated lactic acid production capabilities provide strategic advantages in feedstock control and polymer consistency. The company has also focused heavily on customized polymer development for pharmaceutical clients seeking specific degradation kinetics and drug release profiles. Corbion is estimated to control nearly 16%–19% of global market share in 2026.

Ashland continues strengthening its presence through the Viatel and Viatel Ultrapure polymer product lines. The company is increasingly visible in long-acting injectable therapeutics and implantable drug delivery systems requiring highly controlled polymer purity. Viatel Ultrapure polymers are gaining adoption in microsphere formulations and advanced biologic delivery technologies because of their narrow molecular weight distribution and improved formulation reproducibility.

Ashland has also benefited from rising pharmaceutical outsourcing trends, especially among companies developing peptide therapeutics and chronic disease injectables. Its share in the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market is estimated in the range of 9%–11%, with faster growth visible in high-purity injectable applications.

Mitsubishi Chemical Group remains an important supplier in East Asia, particularly for medical processing materials and specialized biodegradable polymer applications. Japanese manufacturers continue maintaining strong positions in regenerative medicine and advanced surgical materials because of the country’s highly developed medical device sector.

The company’s biodegradable materials are increasingly utilized in tissue regeneration technologies and absorbable implant systems. Japan’s focus on advanced healthcare technologies and regenerative medicine programs continues supporting demand for premium-quality PLGA materials.

PolySciTech, operating under Akina Inc., occupies a more specialized role within the Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market. The company focuses heavily on research-grade polymers, nanoparticle formulations, and customized development materials for pharmaceutical R&D programs. Its polymers are commonly utilized in preclinical formulation studies, experimental microsphere systems, and targeted drug delivery projects.

Although its overall commercial market share remains comparatively smaller, PolySciTech plays an important role in early-stage innovation where pharmaceutical developers require highly customized polymer architectures and rapid formulation flexibility.

Regional manufacturers in China, South Korea, and India are also increasing their presence in the market, particularly in pharmaceutical contract manufacturing and localized medical device production. Chinese companies have expanded biodegradable polymer manufacturing capacity substantially between 2024 and 2026 as domestic injectable drug production increased. South Korean firms are gaining attention because of government-supported biologics manufacturing investments and rising exports of medical biomaterials.

Despite growing regional competition, premium pharmaceutical-grade PLGA remains heavily concentrated among established Western and Japanese suppliers because of strict regulatory qualification requirements. Injectable therapeutics developers continue prioritizing suppliers with proven drug master file support, batch reproducibility, and long-term GMP compliance records.

Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market Share by Manufacturers

The top five manufacturers collectively control approximately 68%–72% of the global Medical-Grade Poly(lactic-co-glycolic acid) (PLGA) Market in 2026. Market concentration remains relatively high because pharmaceutical companies prefer long-term supply continuity for regulated products.

Evonik Industries remains the largest supplier with an estimated share approaching one-third of total global revenues. Corbion follows as the second-largest participant, while Ashland continues gaining share in advanced injectable formulations. Japanese and specialty producers collectively account for a smaller but technologically important portion of the market.

Smaller regional suppliers mainly compete in research-grade materials, pilot-scale production, and cost-sensitive localized medical device applications. However, their participation in regulated injectable pharmaceutical systems remains limited because qualification timelines and regulatory requirements are significantly more stringent.

Competition is increasingly shifting beyond production scale toward formulation support and polymer customization. Pharmaceutical companies developing next-generation sustained-release therapies require suppliers capable of tailoring degradation behavior, intrinsic viscosity, particle morphology, and release kinetics for specific therapeutic targets.

The market is also seeing growing demand for PLGA materials compatible with additive manufacturing technologies. Manufacturers are developing specialized filament and scaffold-grade polymers suitable for 3D-printed implants and regenerative medicine structures. This trend is expected to create additional differentiation opportunities among leading suppliers over the next several years.

Recent Industry Developments

• March 2026: Evonik Health Care expanded commercial support capabilities for RESOMER bioresorbable polymers targeting long-acting injectable therapeutics and implantable medical systems.
• January 2026: Corbion increased development activity around PURASORB biodegradable polymers for orthopedic fixation devices and regenerative medicine applications.
• November 2025: Ashland highlighted expanded utilization of Viatel Ultrapure polymers in advanced injectable delivery systems and biologic therapeutics.
• August 2025: Multiple pharmaceutical CDMOs in North America increased procurement of medical-grade PLGA materials following growth in sustained-release peptide and oncology injectable production.
• July 2025: South Korean biomaterials manufacturers expanded GMP-certified biodegradable polymer processing infrastructure to support export-oriented biologics manufacturing.
• 2025–2026: Regenerative medicine research involving PLGA scaffolds accelerated across Japan, the United States, and Germany, particularly in bone regeneration and vascular tissue engineering applications.